Literature DB >> 1388848

Cellular latency of human immunodeficiency virus type 1.

R J Pomerantz1, O Bagasra, D Baltimore.   

Abstract

The infection of humans by human immunodeficiency virus type 1 is characterized by a prolonged stage of clinical quiescence. This clinically asymptomatic period may be based, in part, on the development of cell populations within the body that maintain human immunodeficiency virus type 1 in a state of latency. Recent advances in the understanding of the molecular mechanisms involved in various forms of cellular latency of human immunodeficiency virus type 1 have begun to shed light on the variable period of asymptomatic infection. The elucidation of cellular retroviral latency, in vivo, will also be critical to the design of novel therapeutic approaches with which to combat human immunodeficiency virus type 1 infections.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1388848     DOI: 10.1016/s0952-7915(06)80042-7

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  4 in total

1.  A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency.

Authors:  S Emiliani; C Van Lint; W Fischle; P Paras; M Ott; J Brady; E Verdin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 2.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

3.  Human immunodeficiency virus type 1 RNA expression by four chronically infected cell lines indicates multiple mechanisms of latency.

Authors:  S T Butera; B D Roberts; L Lam; T Hodge; T M Folks
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

4.  Restriction of human immunodeficiency virus type 1 production in a human astrocytoma cell line is associated with a cellular block in Rev function.

Authors:  M Neumann; B K Felber; A Kleinschmidt; B Froese; V Erfle; G N Pavlakis; R Brack-Werner
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.